Terms: = Prostate cancer AND DDX5, HLR1, 1655, ENSG00000108654, P17844, DKFZp686J01190, p68, G17P1, HUMP68 AND Treatment
12 results:
1. Role of the DEAD-box RNA helicase ddx5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influence.
Li F; Ling X; Chakraborty S; Fountzilas C; Wang J; Jamroze A; Liu X; Kalinski P; Tang DG
J Exp Clin Cancer Res; 2023 Aug; 42(1):213. PubMed ID: 37596619
[TBL] [Abstract] [Full Text] [Related]
2. Guidelines for Sexual Health Care for prostate cancer Patients: Recommendations of an International Panel.
Wittmann D; Mehta A; McCaughan E; Faraday M; Duby A; Matthew A; Incrocci L; Burnett A; Nelson CJ; Elliott S; Koontz BF; Bober SL; McLeod D; Capogrosso P; Yap T; Higano C; Loeb S; Capellari E; Glodé M; Goltz H; Howell D; Kirby M; Bennett N; Trost L; Odiyo Ouma P; Wang R; Salter C; Skolarus TA; McPhail J; McPhail S; Brandon J; Northouse LL; Paich K; Pollack CE; Shifferd J; Erickson K; Mulhall JP
J Sex Med; 2022 Nov; 19(11):1655-1669. PubMed ID: 36192299
[TBL] [Abstract] [Full Text] [Related]
3. ddx5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.
Le TK; Cherif C; Omabe K; Paris C; Lannes F; Audebert S; Baudelet E; Hamimed M; Barbolosi D; Finetti P; Bastide C; Fazli L; Gleave M; Bertucci F; Taïeb D; Rocchi P
Mol Ther; 2023 Feb; 31(2):471-486. PubMed ID: 35965411
[TBL] [Abstract] [Full Text] [Related]
4. Resveratrol directly targets ddx5 resulting in suppression of the mTORC1 pathway in prostate cancer.
Taniguchi T; Iizumi Y; Watanabe M; Masuda M; Morita M; Aono Y; Toriyama S; Oishi M; Goi W; Sakai T
Cell Death Dis; 2016 May; 7(5):e2211. PubMed ID: 27148684
[TBL] [Abstract] [Full Text] [Related]
5. Commentary on: "Long-term functional outcomes after treatment for localized prostate cancer." Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Department of Urologic Surgery and the Center for Surgical Quality and Outcomes Research, Vanderbilt University, Nashville, TN.: N Engl J Med 2013;368(5):436-45. doi: 10.1056/NEJMoa1209978.
Eggener S
Urol Oncol; 2014 May; 32(4):513-4. PubMed ID: 24767688
[TBL] [Abstract] [Full Text] [Related]
6. DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells.
Iio A; Takagi T; Miki K; Naoe T; Nakayama A; Akao Y
Biochim Biophys Acta; 2013 Oct; 1829(10):1102-10. PubMed ID: 23932921
[TBL] [Abstract] [Full Text] [Related]
7. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ
BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568
[TBL] [Abstract] [Full Text] [Related]
8. Long-term functional outcomes after treatment for localized prostate cancer.
Resnick MJ; Koyama T; Fan KH; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Potosky AL; Stanford JL; Stroup AM; Van Horn RL; Penson DF
N Engl J Med; 2013 Jan; 368(5):436-45. PubMed ID: 23363497
[TBL] [Abstract] [Full Text] [Related]
9. PDGF upregulates Mcl-1 through activation of β-catenin and HIF-1α-dependent signaling in human prostate cancer cells.
Iqbal S; Zhang S; Driss A; Liu ZR; Kim HR; Wang Y; Ritenour C; Zhau HE; Kucuk O; Chung LW; Wu D
PLoS One; 2012; 7(1):e30764. PubMed ID: 22276222
[TBL] [Abstract] [Full Text] [Related]
10. Rectal function following prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Galbreath RW; Blatt H; Lief JH
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):667-74. PubMed ID: 11020562
[TBL] [Abstract] [Full Text] [Related]
11. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
[TBL] [Abstract] [Full Text] [Related]
12. [Clinical evaluation of serum basic fetoprotein in patients with urogenital malignancies and renal transplantation].
Seguchi T; Sugao H; Takahara S; Nakano E; Ishibashi M; Sonoda T
Hinyokika Kiyo; 1991 Nov; 37(11):1475-9. PubMed ID: 1722636
[TBL] [Abstract] [Full Text] [Related]
